Velosity Announces Commercial Excellence Enhancements to Fuel Strategic Growth
Internal organizational changes seek to keep Velosity above market trends and apace of new opportunities in the medical and defense sectors.
Thomas Caron (left), Greg Fischer (middle) and Darren Bjork (right). Source (All Images) | Velosity
Velosity, a state-of-the-art, custom contract manufacturer and solutions provider to the medical and defense industries, has announced an update to its commercial excellence framework aimed at outpacing market demands and fueling sustained growth. These organizational changes, effective as of March 18, 2024, further position the company to capitalize on emerging opportunities in both sectors.
In response to the positive momentum and encouraging market shifts, Velosity has appointed Tom Caron as vice president (VP) of sales and defense. With decades of experience and a clear vision for success, Caron will spearhead the architecting of the structure and skill sets necessary to meet the anticipated growth in defense markets. His expertise will be instrumental in ensuring Velosity’s competitiveness in securing high-value contracts within the defense sector.
Joining Velosity in a pivotal leadership capacity is Greg Fischer, appointed as VP of sales and medical. Fischer brings extensive expertise in injection molding, moldmaking and contract manufacturing, having previously served as corporate VP of sales and marketing for National Mold and VP of sales for iMark Molding. In his new role, Fischer will drive sales outreach efforts, with a particular emphasis on partnering with industry leaders in the MedTech, pharmaceutical and life sciences segments within healthcare.
Lastly, elevating Velosity’s commercial capabilities further, Darren Bjork has been promoted to the role of senior VP, commercial. In this newly established position, Bjork will lead medical sales and marketing initiatives, focusing on high-growth clinical areas within the medical space. With a commitment to setting the vision and commercial strategy for above-market performance, Bjork’s leadership will play a pivotal role in positioning Velosity for long-term success.
Dave Hemink, CEO, has expressed excitement about the company’s ability to invest in and further accelerate its commercial excellence and larger go-to-market strategy, crediting Caron for building a “best-in-class” organization. He also extends congratulations to Bjork on his well-deserved promotion and welcomes Fischer to the Velosity team.
“These enhancements underscore our commitment to staying ahead of market trends and delivering value to our customers,” says Dave. “We are confident that the collective expertise of our leadership team, combined with our innovative solutions, will position Velosity for continued success in both the medical and defense sectors.”
As Velosity embarks on this new chapter, the company invites its partners, stakeholders, and employees to join in celebrating the achievements of its dedicated team members and the opportunities that lie ahead.
